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Objectives: To investigate the mental health of rheumatic diseases patients and 
explore the effect of psychotherapy for the mental health status in rheumatism inpa-
tients. MethOds: 1. To compare the mental health status in rheumatism inpatients 
with normal by SCL-90 score. 2. 66 inpatients with rheumatism were recruited in 
the study and randomly divided into study group (n= 33) and control group (n= 33). 
The patients in the study group accepted psychotherapy and pharmacotherapy, and 
control group only accepted pharmacotherapy. 3. Six weeks later, the effect of psycho-
therapy to rheumatism inpatients were assessed by comparing the score of SCL-90 
between the two groups. Results: 1. The SCL-90 score significantly increased in 
rheumatism inpatients group compared with normal group: rheumatism inpatients 
group (152.8±35.9) and normal group (129.9±38.7), (P< 0.05). 2. Six weeks later, the SCL-
90 sore of study group was lower than that of control group. 3. The SCL-90 score sig-
nificantly reduced after psychological treatment. cOnclusiOns: The mental health 
status of rheumatism patients can not be ignored, because the patients have varying 
degrees of mental psychotic symptoms. The psychotherapy can improve the mental 
health status in rheumatism patients and can help the recovery of the patients.
RespiRatoRy-Related disoRdeRs – Clinical outcomes studies
pRs1
the effeCtiveness and safety of febuxostat : an expeRienCe in 
MediCal CenteR in taiwan
Wang Y.S., Ng S.P., Kuo L.H., Chien S.Y.
Changhua Christian Hospital, Changhua City, Taiwan
Objectives: The aim of this study was to assess the effectiveness and safety of 
febuxostat for chronic gout. MethOds: We retrospectively review patients with 
diagnosis of gout (ICD-9 250) concomitant with febuxostat during Jun 2012 to Dec 
2013 in Changhua Christian Hospital. Patients with prescription of febuxostat less 
than 30 days were excluded. We collect the data of patient age, sex and analyzed the 
progression of renal function (eGFR) and uric acid. Prescribed Daily Dose (PDD) of 
febuxostat was calculated. Hospital-based spontaneous reporting systems databases 
were survey for the febuxostat adverse reaction reporting. Results: A total of 151 
patients were included with mean age 68.3±14.4 years. There were 40 female and 111 
male ( F:M ; 1:2.8).The average duration of prescription was 148.0±88.5 days. Prescribed 
Daily Dose (PDD) of febuxostat was 44mg. The uric acid was decrease from 9.1±1.9 to 
6.6±2.7mg/dL. The eGFR was increased from 33.5±23.5 to 34.9±25.1 ml/min/1.73m2. 
86.7% (131) of patients with eGFR < 60 ml/min/1.73m2 at the baseline. In subgroup 
analysis, 42 patients with the duration of prescription 31-90 days (average 55.8±15.6 
days ), 59 patients with 91-180 days(average 127.6±25.6 days), 50 patients with > 181 
days (average 249.6±68.77 days), the uric acid derement was 2.3±2.8 mg/dL, 2.6±2.9 
mg/dL and 2.8±2.1 mg/dL respectively. A total of 6 cases reported as mild adverse 
reaction, 4 cases reported as skin reaction. Other reactions reported was chills and 
insomnia.The incidence of ADR was 3.97%.(6/151). cOnclusiOns: Febuxostat is an 
effective urate-lowering agent. We found a trend that the longer Febuxostat use, the 
more uric acid decline. The safety of febuxostat was well tolerated since the adverse 
reaction reported was mild. The total 6 cases adverse reaction reported were occurred 
in eGFR < 60 ml/min/1.73m2. Therefore, we need to closed monitor adverse reaction 
in CKD patients.
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inhaled antiCholineRgiCs and Risk foR aCute uRinaRy Retention: a 
Case-CRossoveR and Case-tiMe-ContRol study
Lin F.J.1, Joo M.J.2, Pickard A.S.2, Dilokthornsakul P.3, Lee T.A.2
1Pharmerit International, Bethesda, MD, USA, 2University of Illinois at Chicago, Chicago, IL, USA, 
3Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, 
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Objectives: Recent nested case-control studies have raised concerns of the risk for 
acute urinary retention (AUR) among patients receiving tiotropium, a long-acting 
inhaled anticholinergic. In this study, we examined the effect of inhaled anticho-
linergics on the occurrence of AUR using self-controlled methods, case-crossover 
and case-time-control designs, which adjust for all time-invariant confounders and 
reduce threat of control-selection bias. MethOds: Patients aged ≥ 45 years with 
chronic obstructive pulmonary disease (COPD) were included from the IMS LifeLink 
Health Plan Claims Databases. Cases with AUR in both inpatient and outpatient set-
tings during 2006-2009 were identified. In the case-time-control approach, ten con-
trols were randomly selected for each case after matching age, gender, geographic 
location, to control for the secular trend of medication use. Exposure to tiotropium, 
ipratropium, and medications with significant anticholinergic effects was deter-
mined in the 30-day period prior to the event and in a 30-day reference period which 
was 180 days prior. Multivariate conditional logistic regression was used to evaluate 
the association between anticholinergic exposure and AUR, with sensitivity analyses 
and subgroup analyses based on age, gender and related comorbidities. Results: A 
total of 6,008 cases and 60,080 controls were identified. The mean age was 74 years 
and ~78% were male. In the case-crossover analysis, adjusted odds ratio (OR) of AUR 
was 1.34 (95%CI 1.13-1.60) for tiotropium and 1.19 (1.00-1.41) for ipratropium. In the 
case-time-control analysis, the risk of AUR OR was 1.24 (1.03-1.50) for tiotropium and 
1.26 (1.05-1.51) for ipratropium. The AUR risk related to tiotropium and ipratropium 
was similar among patients aged > 75 years, males, and those with benign prostate 
hyperplasia, prostate cancer, and diabetes. cOnclusiOns: Our results support cur-
rent evidence that use of inhaled anticholinergics is associated with higher risk for 
AUR (odds increased by 20-35%) in COPD patients. Providers should be aware of the 
potential risk for AUR when making treatment decisions.
pRs3
Cough as a key syMptoM in asthMa, alleRgiC Rhinitis, Copd and 
Rhinosinusitis and its iMpaCt in asia
Wang D.Y.1, Ghoshal A.G.2, Razak Bin Abdul Muttalif A.3, Lin H.C.L.4, Thanaviratananich S.5, 
Bagga S.6, Faruqi R.7, Brnabic A.J.M.8, Dehle F.C.8, Cho S.H.9
and humanistic) requirements to support reimbursement and prescription of bio-
similar drugs in three Asian markets (Japan, South Korea and China). MethOds: 
We conducted secondary research to review the macroeconomic factors impact-
ing biosimilar entry (regulatory policy, intellectual property protection etc.) Payer/ 
physician guidance and positions on biosimilar use across markets and diseases 
were also reviewed. Following this, primary research was conducted with a mix of 
payers and physician stakeholders to understand: 1. The therapy areas that payers/
physicians consider most attractive for biosimilars; 2. Payer/physician value drivers 
and evidence requirements (bioequivalence, comparative data etc.) across therapy 
areas that would support public reimbursement and prescription. 3. Expectations 
around price differentials vs. branded biologics and the implications these 
differentials have on access and utilization of biosimilars. Results: Evidence 
requirements vary by market, with Japan and S.Korea being fairly consistent while 
China having lower thresholds. Evidence requirements also tend to vary by therapy 
area and complexity of the biologic. Overall, efficacy/ safety data and price are key 
value drivers for biosimilar reimbursement and uptake. In the absence of com-
parative data vs. the branded biologic, concerns around safety/efficacy may impact 
uptake but the promise of significant budget savings supports positive reimburse-
ment/ access decisions. cOnclusiOns: The access environments for biosimilars in 
the developed markets of Japan and S.Korea can be expected to be similar to other 
developed markets across the world. However, China is likely to be more favourable 
than the developed markets when it comes to access and uptake of biosimilars.
pMs30
Closing the gap: ReduCed delay to dRug MaRketing appRoval 
between the west and asia
Hamilton K.A., Eddowes L., Brooks-Rooney C.
Costello Medical Consulting Ltd., Cambridge, UK
Objectives: Historically, there has been a delay between the marketing approval of 
drugs in Western countries and other markets worldwide. However, the pharmaceuti-
cal market in Asia is rapidly expanding (a projected increase in global market share of 
7% from 2000–2016). The objective of this analysis was to investigate patterns of drug 
approvals in Western and Asian countries. MethOds: National English-language 
drug regulatory authority websites were searched for drug approval dates in key 
Western (United States and European Union) and Asian countries (Japan, Hong Kong, 
Indonesia and Singapore) in type 2 diabetes mellitus (T2DM) and rheumatoid arthritis 
(RA). For drugs with ≥ 1 approval in each region, we analysed how the delay in average 
approval date between the West and Asia changed over time. Results: At least 1 
West and 1 Asian approval was recorded for 21 drugs (T2DM n= 12, RA n= 9), out of the 
31 included. The delay between approval in the West and Asia was found to decrease 
between 2000 and 2014 in both T2DM and RA, and there was an overall strong negative 
correlation between the date of first approval and the delay (p< 0.0001; Spearman Rank 
correlation). Despite the delay for RA drugs (mainly biologics) being over double that 
of the T2DM (all small molecules) in 2000 (8.6 vs 3.6 years), by 2009 the delay for drugs 
in both indications was less than 2 years, due to a greater rate of decrease in delay for 
RA. cOnclusiOns: Whilst the current analysis has limitations, it is clear that the 
delay in date of approval of T2DM and RA drugs in Western and APAC countries has 
decreased dramatically over the past decade. This may have an impact on the future 
marketing strategies of pharmaceutical companies. Further analysis would be needed 
to ascertain if this same trend is observed in other emerging markets.
pMs31
health liteRaCy and health CaRe utilization aMong adults with 
osteopoRosis
Rasu R.1, Agbor Bawa W.1, Rianon N.2
1University of Missouri-Kansas City, Kansas City, MO, USA, 2University of Texas Health Science 
Center- Houston, Houston, TX, USA
Objectives: Every year, osteoporosis accounts for two million fragility fractures 
leading to disability, decreased quality of life and increased health care cost. Health 
literacy poses a challenge in delivering effective health care services. Impact of 
health literacy on health care utilization in the osteoporotic patients is unknown. 
We describe(1) health care utilization for osteoporosis patients in the USA(2) their pre-
scription drug expenses, and(3) examine any effects that health literacy may have on 
the above factors. MethOds: This cross-sectional analysis used Medical Expenditure 
Panel Survey(MEPS) survey data from 2005 - 2008 and patients were identified using 
ICD-9 codes (733.xx) for osteoporosis. Patients’ health literacy levels(HLL) were 
determined by using the health literacy scores(HLS), rated using the 2003 National 
Assessment of Adult Literacy to levels from basic or below basic(BBHLL< 226) to above 
basic (ABHLL≥ 226) (range 0–500). The outcome variables were visits and costs as a 
function of HLL adjusted for other covariates. Adjusted logistic regression analyses 
determined factors that might influence HLL in osteoporotic patients. Results: 
Majority of the total of 915 (20,486,934 weighted) individuals (mean age, 67.4; SD±11.7) 
were women (92%), Caucasians (91%) and on bisphosphonates (78%). The estimated 
national mean of HLS was 220.3(SD±27.5). Average annual visits and visits expenditure 
were 13.9 and $1,587 respectively. Individuals with ABHLL incurred less annual visits 
(13.4 vs 14.3) but paid more per visit ($130vs.$103) compared to those with BBHLL. 
Self-perceived health status( SPHS) was rated 2.35 times greater by ABHLL than those 
with BBHLL (OR:2.352,CI:1.43,-3.87). Patients with polypharmacy(> 4 drugs) were 1.87 
times less likely to have ABHLL(P< 0.0001) than those with BBHLL. cOnclusiOns: 
Osteoporosis patients with ABHLL incurred less annual visits but paid more per visit. 
While increasing HLL may not decrease visits or expenditure per visit, it may decrease 
drug expenses, polypharmacy and improve SPHS, all associated with better health 
care outcomes.
pMs32
the iMpaCt of psyChologiCal tReatMent of RheuMatiC patients with 
Mental health
Liu X.Y.1, Wang S.1, Liu D.2, Huang Y.2
1The mental Health Center of xi’an, xi’an, China, 2The Fifth Hospital of Xi’an, Xi’an, China
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faCtoRs affeCting the out-CoMe in hospital aCquiRed pneuMonia
Kunhikatta V.1, Rau N.R.2, Naik A.N.1, Thunga G.1, Nair S.1, Yamsani B.1
1Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India,, 2Kasturba 
Medical College, Manipal University, Manipal, India
Objectives: To analyze the risk factors associated with the out-come of hospital 
acquired pneumonia (HAP). MethOds: A prospective observational study, carried 
out in a tertiary care teaching hospital. HAP patients who fulfill the inclusion criteria 
were identified and enrolled into the study after taking informed consent. Patients 
were followed from the day of diagnosis of HAP to till the day of discharge/death. 
The patient data like demography, social habits, co-morbid diseases, interventions 
(mechanical ventilation), severity assessment (APACHE II score) and clinical out-
come (discharge or death) were recorded in the case record forms. Univariate and 
Multivariate analysis were used to determine the association of the studied risk 
factors with clinical out-come. Results: Total of 505 patients were enrolled in the 
study. Among 505 HAP patients, 417 were improved and discharged; remaining 88 
patients were expired. The mean age of study patient population was 55.1±16.2 years 
and 38.4% patients were more than 60 years of age. The majority of patients were 
males n= 338 (66.9%). 230 (45.5%) patients were ventilated during their stay in the 
hospital. Twelve variables (age> 60 years, sex, mechanical ventilation, APACHE-II> 20, 
cardiac, pulmonary, renal, immunosuppression, diabetes mellitus, liver insuffi-
ciency, smoking and alcohol intake) were analyzed for possible association with the 
clinical outcome of HAP in Univariate analysis. Variables with statistical significance 
during the Univariate analysis were entered into the multivariate analysis. The 
following five variables were found statistically significant independent predic-
tors of out-come (mortality) in these patient population in multivariate analysis 
using logistic regression: mechanical ventilation (OR: 9.81; CI:4.98-19.35; p< 0.001), 
immunosuppression (OR:4.31; CI:1.65-11.27 ; p< 0.003), liver insufficiency (OR:3.69; 
CI:1.43-9.55; p< 0.007), APACHE II> 20 (OR:2.72; CI:1.56-4.76 ; p< 0.001) and male sex 
(OR:2.27; CI: 1.71-4.38; p< 0.015). cOnclusiOns: HAP has contributed significantly 
to mortality (17.4%). Mechanical ventilation, immunosuppression, Liver insuffi-
ciency, APACHE II score > 20 and male sex were found to be independent predictors 
of mortality in HAP patients.
pRs8
analysis of faCtoRs Causing ChRoniC obstRuCtive pulMonaRy 
disease in easteRn Region of China
Shu B.
University College London, London, England
Objectives: Chronic Obstructive Pulmonary Disease (COPD) has become increas-
ingly a major public health problem. This study aimed to evaluate the risk factors 
for COPD based on data from several cities in eastern region of China. MethOds: 
Data were extracted from China Health Statistics for five most representative cities 
and provinces (Liaoning, Beijing, Tianjing, Shanghai and Guangdong) in the east-
ern region of China where rates of COPD were available. Descriptive statistics and 
multiple regression models were used to examine risk factors for COPD including 
gender, average family expenditure on cigarette, industrial dust, industrial emis-
sion of sulfur dioxide, average family income and average family expenditure on 
vegetables. Results: The total sample size was 150. Descriptive statistics indi-
cated strong correlations between the dependent variable rate of COPD and inde-
pendent variables – average family expenditure on cigarette, industrial emission 
of sulfur dioxide, industrial dust and average family expenditure on vegetables. 
Furthermore, multiple regression models showed that average family expenditure 
on cigarette, industrial emission of sulfur dioxide, industrial dust and average family 
expenditure on vegetables were the significant parameters that affected the rate of 
COPD. cOnclusiOns: Our analyses showed that, in the eastern region of China, 
cigarette smoking, sulfur dioxide emission, industrial dust and family expendi-
ture on vegetables were independent risk factors associated with the occurrence 
of COPD. To lessen the occurrence of COPD, people should quit smoking and modify 
dietary habit, while government authorities should enforce controlling for sulfur 
dioxide and industrial dust emissions.
RespiRatoRy-Related disoRdeRs – Cost studies
pRs9
inCidenCe-based Cost of asthMa in vietnaM
Nguyen N.B.T.1, Nguyen T.T.T.2
1University of Medicine and Pharmacy in HCMC, HCMC, Vietnam, 2University of Medicine and 
Pharmacy in HCMC, Ho Chi Minh City, Vietnam
Objectives: Nowadays, health care costs of asthma are under pressure in all coun-
tries due to high prevalence, incidence and the chronic nature of disease. Hence, the 
aim of the study is to evaluate the lifetime cost of asthma for every new case and the 
incidence-based economic burden of asthma in Vietnam. MethOds: A Markov model 
with 5 states, including mild, intermittent, moderate and severe, has been built. The 
model has a cycle length of 1 year with the time horizon of life time. The population 
of 1000 new cases has been included in the model. The transition rates between states 
have been retrieved from relevant epidemiological studies, clinical trials and experts’ 
opinions. The treatment costs of asthma have been totaled for the life-time horizon 
using discount rate of 3%. The study has been conducted based on the perspective of 
insurance companies, therefore only direct medical costs have been evaluated. The 
prices of drugs and medical services have been averaged from the price-lists in 2013 
of some major hospitals in Vietnam. Results: The incidence-based cost of every new 
case of asthma in Vietnam accounts for 70,019,897 VND, in which costs for drugs and 
medical services account for 60.55% and 39.45%, respectively. The cost for diagnos-
ing and management of asthma within life-time per capita is 51,459,674 VND, which 
is around 2.77 times higher than for the costs of asthma exacerbations treatment 
(18,560,224 VND). With nearly 231,260 new cases of asthma annually, Vietnam has 
1National University of Singapore, Singapore, 2National Allergy Asthma Bronchitis Institute, 
Kolkata, India, 3Institute of Respiratory Medicine, Kuala Lumpa, Malaysia, 4Chang Gung Memorial 
Hospital, Taoyuan Hsien, Taiwan, 5Khon Kaen University, Khon Kaen, Thailand, 6Merck & Co., Inc., 
New Jersey, NJ, USA, 7Merck & Co., Inc., Singapore, 8Optum, Sydney, Australia, 9Seoul National 
University Hospital, Seoul, South Korea
Objectives: Respiratory diseases represent significant impact on health 
care resources. A cross-sectional, observational study, Asia-Pacific Burden of 
Respiratory Diseases (APBORD), was conducted to examine burden of disease 
in adults with respiratory diseases across 6 countries - India, Korea, Malaysia, 
Singapore, Taiwan, and Thailand. We examined the extent to which cough is a 
presenting symptom and reason for medical visits for participants with Asthma, 
Allergic Rhinitis (AR), COPD or Rhinosinusitis. MethOds: Participants aged ≥ 18 
years, presenting to a physician with primary diagnosis of Asthma, AR, COPD or 
Rhinosinusitis were enrolled. Participants completed a survey which contained 
questions related to demographics, respiratory symptoms, health care resource 
use and quality of life. Results: A total of 13,902 participants were screened, of 
which 7,030 were eligible and 5,250 enrolled. The highest percentage of partici-
pants receiving care for a respiratory disorder had primary diagnosis of AR 14.0%, 
(95%CI: 13.4%, 14.6%), followed by Asthma 13.5% (12.9%, 14.1%), Rhinosinusitis 
5.4% (4.6%, 5.3%) and COPD 4.9%, (5.0%, 5.7%). Cough or coughing up phlegm was 
reported as symptom by more than half the participants. Cough or coughing up 
phlegm was reported as the main reason for medical visit by more than 20% of 
participants. Among all symptoms reported, cough was most frequently reported 
by participants with a primary diagnosis of COPD (73%), followed by Asthma (61%), 
Rhinosinusitis (59%), and AR (47%). In addition, cough was the most frequently 
reported main reason for seeking medical care among participants with a pri-
mary diagnosis of COPD (43%), for Asthma (33%), for Rhinosinusitis (13%), and for 
AR (11%). cOnclusiOns: Cough is a prominent symptom and major driver of 
medical care for patients with Asthma, Allergic Rhinitis, COPD or Rhinosinusitis. 
These data suggest that patients presenting with cough should be investigated 
comprehensively for any underlying more serious respiratory disorders to help 
with appropriate disease management.
pRs4
pollen MoRphology and total pRotein of taRaxaCuM offiCinale and 
asteR alpinus
Janyerkye T., Munkhbayarlakh S., Narantsetseg L.
Health Sciences University of Mongolia, Ulaanbaatar, Mongolia
Objectives: The aerborne allergenic content of the atmosphere varies accord-
ing to climate, geographyand vegetation. Furthermore, in the last few years, 
experimental data on pollen and subpollen-particles structure, the pathogenetic 
role of pollen and the interaction between pollen and air pollutants, gave new 
insights into the mechanisms of respiratory allergic diseases.We aim to evaluate 
Pollen morphology and total protein of Taraxacum officinale and Aster alpinus. To 
determine the Pollen morphology and total protein of Taraxacum officinale and 
Aster alpinus. MethOds: The Research is been done under the Biochemistry and 
Laboratory Department of Biomedicine School, HSUM with the help of Laboratory 
of School of Health Technology. Pollen morphology of Taraxacum officinale and 
Aster alpinus was investigated by light and microscopy. And total proteins was 
detected by Lowry method. Results: In Taraxacum pollen grain size (polar- egua-
toral diameter) ranged from 29.5±0.77 (24.7-34.6) µm to 25.1±0.76 (21.4-30.4) µm. 
And total proteins content 0.4mg/ml. Pollen grain of Aster alpinus size ranged from 
34.4±2.4 (22.7-38.5) µm to 22.7±0.88 (19.6-26.09) µm. Total proteins was contents 
0.9mg/ml. Both pollen walls are echinated, exine coated circular and yellow oil 
droplets. cOnclusiOns: Findings from the pollen grains comparison of mor-
phologic parameters demonstrated that the Aster alpinus pollen was larger than 
Taraxacum pollen.
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a Method to investigate seasonal vaRiation in hospitalization foR 
Copd in a MidwesteRn us state
Su W.1, Zhao R.1, Heins-Nesvold J.2, Carlson A.1
1University of Minnesota, Minneapolis, MN, USA, 2American Lung Association of the Upper 
Midwest, st paul, MN, USA
Objectives: To investigate the impact of seasonal variation on daily number 
of COPD hospital admissions using 6 years of hospital discharge data from the 
Iowa Hospital Association. MethOds: Inpatient admissions from 2006 to 2011 for 
persons 30 years of age or older were included if there was a principal ICD-9-CM 
diagnosis of COPD (491.xx; 492.xx; 496.xx).Generalized linear models extending 
Poisson regression and Negative Binomial model (to account for overdispersion) 
were fitted. Admission date was converted into an angle calledθ and treated as 
a continuous variable with a circular distribution. Sinθ and cosθ together were 
proposed to be used as the covariates representing seasonal effect. Subgroup 
analyses of age and sex were applied. Results: 34,563 inpatient admissions for 
COPD were identified. Admissions for COPD showed a strong seasonal pattern 
(P< 0.0001). The number of hospital admissions reached its maximum on Feb.21 
and its minimum on Aug. 23. The distribution is symmetric around the year. There 
were no differences of maximum and minimum dates between male, female and 
the overall population. However, for patients older than 65 years of age, the num-
ber of hospital admissions reached its maximum on Feb.25 and its minimum on 
Aug. 27. For patients 30-65 years of age, its maximum was on Feb.11; its mini-
mum was on Aug.12. The peaks were two weeks earlier than patients older than 
65 years of age. cOnclusiOns: The present findings support the conclusion that 
COPD hospitalization is higher in the winter. However, the busy period tends to 
be in late winter from Jan.7 until Apr.7, suggesting that it may be arbitrary to 
simply define winter as December to February when studying seasonal effect of 
COPD in the Midwest. The analytic method and the outcome of this study may 
help to allocate health care resources efficiently based on seasonal hospitaliza-
tion trend.
